Filing Flows

Filing Flows › Health Care › Prestige Consumer Healthcare (PBH)

Prestige Consumer Healthcare (PBH) earnings and revenue breakdown

Latest: Q2 FY27 · 10-Q filed Nov 5, 2026 · Prestige Consumer Healthcare (PBH) Q2 FY27 earnings results →

Q2 FY27 Revenue up 23% year over year to $336M · 8¢ of every $1 of revenue kept as net profit · operating margin 24.0%

Prestige Consumer Healthcare made $336M in Q2 FY27 (+23% Y/Y): Gastrointestinal $63.1M, Women's Health $53.6M, Wellness, Sleep & Other $47.3M. Operating margin 24.0%, net earnings $25.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.

Revenue$336M
Year over year+23%
Operating margin24.0%
Net earnings$25.3M
Operating cash flow$37.9M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $336.3M in Q2 FY27, up 23% year over year and up 27% from the previous quarter. Gastrointestinal was the largest line at 19% of revenue. Wellness, Sleep & Other added $40.9M year over year (up 639%), 66% of the total change. Gastrointestinal declined 2%.

Gross margin was 51.3%, down 4.0 points from Q2 FY26. Operating profit was $80.7M, a 24.0% margin (down 5.1 points year over year). Of the extra revenue versus Q2 FY26, 2% reached operating profit, below the 29% margin then. Operating expenses grew 28% against revenue growth of 23%. The fastest-growing cost line was Other operating costs (+68%). Net earnings were $25.3M, down 40% year over year. The effective tax rate was 46.7%.

Operating cash flow was $37.9M (down 34% year over year), 150% of net earnings. Non-cash charges added back $12.0M of depreciation and amortization and $1.2M of share-based compensation. Capital expenditures of $3.6M left free cash flow of $34.2M.

Quarterly history

Prestige Consumer Healthcare revenue by quarterPrestige Consumer Healthcare revenue by quarter$297MQ4 FY25$250MQ1 FY26$274MQ2 FY26$283MQ3 FY26$282MQ4 FY26$266MQ1 FY27$336MQ2 FY27
Prestige Consumer Healthcare net earnings by quarterPrestige Consumer Healthcare net earnings by quarter$50.1MQ4 FY25$47.5MQ1 FY26$42.2MQ2 FY26$46.7MQ3 FY26$53.9MQ4 FY26$29.2MQ1 FY27$25.3MQ2 FY27
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q2 FY2710-QNov 5, 2026$336M+23%24.0%$25.3M$37.9M
Q1 FY2710-QAug 6, 2026$266M+6%19.8%$29.2M$70.8M
Q4 FY2610-KMay 14, 2026$282M-5%26.8%$53.9M$42.8M
Q3 FY2610-QFeb 5, 2026$283M-2%29.1%$46.7M$78.3M
Q2 FY2610-QNov 6, 2025$274M-3%29.1%$42.2M$57.5M
Q1 FY2610-QAug 7, 2025$250M-7%28.8%$47.5M$79.0M
Q4 FY2510-KMay 9, 2025$297M+7%29.8%$50.1M$61.8M

Charts

Prestige Consumer Healthcare: revenue growth, year over year and quarter over quarterPrestige Consumer Healthcare: revenue growth, year over year and quarter over quarterY/YQ/Q+7%Q4 FY25-7%-16%Q1 FY26-3%+10%Q2 FY26-2%+3%Q3 FY26-5%-1%Q4 FY26+6%-6%Q1 FY27+23%+27%Q2 FY27
Latest (Q2 FY27): Y/Y +23%, Q/Q +27%.
Prestige Consumer Healthcare: where the cash came from (+) and went (−), TTM to Q2 FY27Prestige Consumer Healthcare: where the cash came from (+) and went (−), TTM to Q2 FY27Acquisitions−$1.3BOther financing$1.1BOperating cash flow$230MCash drawn (+) / kept (−)$72.6MBuybacks−$46.5MNet borrowing (+) / repaid (−)−$32.6MCapital spending−$15.6MTaxes on employees’ shares−$2.8MOther investing−$1.8MShares issued$472KExchange rates$323K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Prestige Consumer Healthcare: profit against cash, quarter by quarterPrestige Consumer Healthcare: profit against cash, quarter by quarterNet incomeOperating cash flow$61.0M$65.1MQ3 FY25$50.1M$61.8MQ4 FY25$47.5M$79.0MQ1 FY26$42.2M$57.5MQ2 FY26$46.7M$78.3MQ3 FY26$53.9M$42.8MQ4 FY26$29.2M$70.8MQ1 FY27$25.3M$37.9MQ2 FY27
Latest (Q2 FY27): Net income $25.3M, Operating cash flow $37.9M.
Prestige Consumer Healthcare: diluted shares by fiscal yearPrestige Consumer Healthcare: diluted shares by fiscal year51MFY2151MFY2250MFY2350MFY2450MFY2549MFY26
-3.7% since FY21: buybacks shrank the count.
Prestige Consumer Healthcare: long-term debt falling due (FY26)Prestige Consumer Healthcare: long-term debt falling due (FY26)$400M2028$600MLater
Cash $63.9M, short-term investments —, long-term debt $994M at 2026-03-31.
Prestige Consumer Healthcare in its industry: growth against margin (225 companies, SIC 2834)Prestige Consumer Healthcare in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMPBH (+23%, 24%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

Customers and suppliers named in filings

Sells to

About Prestige Consumer Healthcare

Unless otherwise indicated by the context, all references in this Annual Report on Form 10-K to “we,” “us,” “our,” the “Company” or “Prestige” refer to Prestige Consumer Healthcare Inc. and our subsidiaries. Prior to August 17, 2018, the Company's name was Prestige Brands Holdings, Inc. Reference to a year (e.g., “2026”) refers to our fiscal year ended March 31 of that year. We formed as a Delaware corporation in 1996 and are engaged in the development, manufacturing, marketing, sales and distribution of well-recognized, brand name, over-the-counter (“OTC”) health and personal care products to mass merchandisers, drug/drug wholesale, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets.

In its own words, from its 10-K, filed May 14, 2026.

Prestige Consumer Healthcare against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +23% against the peers' median +10%. Operating margin: 24.0% against the peers' median 24.0%.

CompanyQuarterRevenueY/YOp. margin
PBH Prestige Consumer HealthcareQ2 FY27$336M+23%24.0%
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Prestige Consumer Healthcare 10-Q on SEC EDGAR · CIK 1295947 · Pharmaceutical Preparations

Guidance and outlook

Prestige Consumer Healthcare: what its forward-looking statements are about (10-Q filed 2026-11-05)Prestige Consumer Healthcare: what its forward-looking statements are about (10-Q filed 2026-11-05)Supply chain2Legal & regulation2Demand1Financing1Capital spending1
7 statements; tone +0.29 (−1 all cautious, +1 all confident); 1 hedged.
Prestige Consumer Healthcare: outlook statements against the filing beforePrestige Consumer Healthcare: outlook statements against the filing beforeConfident3Cautious1

13F: who owns PBH and who is buying

Largest holders of PBH (13F)Largest holders of PBH (13F)BlackRock$370MVanguard Group$332MAriel Investments, LLC$230MVanguard Portfolio Management LLC$134MDimensional Fund Advisors LP$126MFuller & Thaler Asset Management$110MVanguard Capital Management LLC$101MState Street$100MBrandes Investment Partners, LP$97.0MKayne Anderson Rudnick Investment…$88.5M
Funds' net buying of PBH by quarter (13F)Funds' net buying of PBH by quarter (13F)$13.8M2024-09−$2.2M2024-12−$29.2M2025-03$16.9M2025-06$9.5M2025-09−$71.9M2025-12$48.2M2026-03$116M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on PBH

History

Every quarter: Q2 FY27 results · Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results

Compare PBH with

中文版：Prestige Consumer Healthcare（PBH）财报

Español · Français